Compare JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) vs Oscar Health Inc (OSCR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Nasdaq Equity Premium Income ETF vs Oscar Health Inc — how do they compare? JPMorgan Nasdaq Equity Premium Income ETF trades at $61.12 (market cap $44.49B), while Oscar Health Inc trades at $33.4 (market cap $10.22B). The key difference: JPMorgan Nasdaq Equity Premium Income ETF is far larger — about 4.4× Oscar Health Inc's market cap, and JPMorgan Nasdaq Equity Premium Income ETF is more actively traded (5,681,789 versus 4,123,394). Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Nasdaq Equity Premium Income ETF for 66 Days and Oscar Health Inc for 15 Days on average.
| JEPQ | OSCR | |
|---|---|---|
Market Cap | $44.49B | $10.22B |
Volume | 5,681,789 | 4,123,394 |
Sector | Income / Options Overlay | Health |
52-Week High | $61.46 | $33.81 |
52-Week Low | $53.77 | $10.85 |
Typical Hold Time | 66 Days | 15 Days |
Enterprise Value | — | $6.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JEPQ trades at $61.07, down 0.33% on the day, with technical indicators showing a bullish moving average signal but neutral oscillators. The ETF's covered-call strategy generates substantial monthly income, with recent dividends ranging from $0.57 to $0.70 per share. Financial media highlights JEPQ's 11% estimated yield and focus on Nasdaq technology exposure, though the strategy limits upside potential during strong bull markets.
JEPQ offers high monthly income through its covered-call approach on Nasdaq-100 stocks, making it attractive for income-focused investors. However, the strategy caps upside growth potential and distributions vary with market volatility. Key risks include concentrated tech exposure and dependence on options market conditions for income generation.
OSCR trades at $33.41, up 1.52% today, with a bullish technical signal and strong recent earnings beats in Q1 and Q2 2026. The stock shows robust revenue growth, with 2026 revenue projected at $15.3B and a return to profitability. Analyst sentiment is mixed but leans positive, with a consensus price target of $34.00. Recent news highlights market share gains and raised 2026 guidance, though the stock faces tests from rising medical costs.
The outlook is cautiously optimistic, driven by scalable growth in the ACA market and margin expansion opportunities. Key risks include medical cost pressures and competitive threats. Upside potential exists if the company executes on its 2029 EPS target of $4+, but investors should monitor profitability sustainability amid cost headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Nasdaq Equity Premium Income ETF
JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.
Read more on JEPQ →About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →
